Ute Rehwald
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Schulz H, Engert A, Diehl V, Schnell R, Borchmann P, Rüdiger T, Driessen C, Elter T, Morschhauser F, Rehwald U, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109-11.
01.01.2008Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
01.01.2008Blood 2008; 111:109-11
Schulz Holger, Engert Andreas, Diehl Volker, Schnell Roland, Borchmann Peter, Rüdiger Thomas, Driessen Christoph, Elter Thomas, Morschhauser Franck, Rehwald Ute, Reiser Marcel
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
Rehwald U, Engert A, Diehl V, Muller-Hermelink K, Rüdiger T, Driessen C, Morschhauser F, Staak J, Sieber M, Reiser M, Schulz H, German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101:420-4.
15.01.2003Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
15.01.2003Blood 2003; 101:420-4
Rehwald Ute, Engert Andreas, Diehl Volker, Muller-Hermelink Konrad, Rüdiger Thomas, Driessen Christoph, Morschhauser Franck, Staak Jan Oliver, Sieber Markus, Reiser Marcel, Schulz Holger, German Hodgkin Lymphoma Study Group (GHSG)